NovoCure Limited (NVCR)
NASDAQ: NVCR · IEX Real-Time Price · USD
12.80
+0.17 (1.31%)
At close: Apr 29, 2024, 4:00 PM
13.02
+0.22 (1.72%)
Pre-market: Apr 30, 2024, 8:00 AM EDT
NovoCure Employees
NovoCure had 1,453 employees on December 31, 2023. The number of employees increased by 133 or 10.08% compared to the previous year.
Employees
1,453
Change (1Y)
133
Growth (1Y)
10.08%
Revenue / Employee
$350,542
Profits / Employee
-$142,493
Market Cap
1.38B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 1,453 | 133 | 10.08% |
| Dec 31, 2022 | 1,320 | 153 | 13.11% |
| Dec 31, 2021 | 1,167 | 144 | 14.08% |
| Dec 31, 2020 | 1,023 | 241 | 30.82% |
| Dec 31, 2019 | 782 | 184 | 30.77% |
| Dec 31, 2018 | 598 | 103 | 20.81% |
| Dec 31, 2017 | 495 | 35 | 7.61% |
| Dec 31, 2016 | 460 | 142 | 44.65% |
| Dec 31, 2015 | 318 | 60 | 23.26% |
| Dec 31, 2014 | 258 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Brookdale Senior Living | 36,000 |
| National HealthCare | 13,123 |
| Omnicell | 3,650 |
| Tilray Brands | 1,600 |
| ANI Pharmaceuticals | 642 |
| Day One Biopharmaceuticals | 155 |
| Akero Therapeutics | 56 |
NVCR News
- 5 days ago - Results of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024 - Business Wire
- 25 days ago - Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024 - Business Wire
- 4 weeks ago - Novocure to Report First Quarter 2024 Financial Results - Business Wire
- 4 weeks ago - Novocure's stock surges after positive results in brain-cancer trial - Market Watch
- 4 weeks ago - Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer - Business Wire
- 4 weeks ago - Novocure's lung cancer therapy succeeds in late-stage trial - Reuters
- 4 weeks ago - METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer - Business Wire
- 7 weeks ago - INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO - Business Wire